SCHEMBL45104

SCHEMBL45104

O=C1NCc2ccccc2N1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.53
AHR P35869 1/20 0.52
PDK2 Q15119 1/20 0.52
PDE3B Q13370 1/20 0.51
PDE3A Q14432 1/20 0.51
NPC1 O15118 2/20 0.50
MAPK13 O15264 1/20 0.50
MAPK12 P53778 1/20 0.50
MAPK11 Q15759 1/20 0.50
MAPK14 Q16539 1/20 0.50
CYP11B1 P15538 2/20 0.49
CYP11B2 P19099 2/20 0.49
MAPT P10636 2/20 0.47
CA12 O43570 2/20 0.47
CA9 Q16790 2/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
BRD4 O60885 2/20 0.46
CREBBP Q92793 2/20 0.46
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyrimidine SCHEMBL29145816 0.89 CYP11B1 (0.52) HTR5AAHRPDK2PDE3BPDE3A
Isoxazole SCHEMBL2309527 0.83 CYP11B1 (0.42) HTR5AAHRPDK2PDE3BPDE3A
SCHEMBL8872856 0.81 CA12 (0.55) HTR5AAHRPDK2NPC1MAPK13
SCHEMBL1196991 0.79 NPC1 (0.57) HTR5AAHRPDK2PDE3BPDE3A
SCHEMBL29546699 0.79 CA12 (0.44) HTR5AAHRPDK2PDE3BPDE3A
SCHEMBL5464714 0.79 AHR (0.48) HTR5AAHRPDK2NPC1MAPK13
SCHEMBL14061414 0.79 CA12 (0.56) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL8126700 0.77 AHR (0.72) AHRPDK2PDE3BPDE3ANPC1
SCHEMBL310398 0.77 HTR5A (0.57) HTR5AAHRPDK2NPC1MAPK13
SCHEMBL6469101 0.77 NPC1 (0.72) HTR5AAHRPDK2NPC1MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118420550-B N-hydroxyamide compound containing dihydroquinazolinone, and preparation method and application thereof 亳州学院 2026-05-22 CN claimed
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 EP claimed
US-12558357-B2 Tetrahydroquinazoline derivatives as selective cytotoxic agents MERCK SHARP & DOHME LLC (US) 2026-02-24 US claimed
US-12492183-B2 Tetrahydroquinazoline derivatives as selective cytotoxic agents MERCK SHARP & DOHME LLC (US) 2025-12-09 US claimed
EP-4638538-A1 LIQUID RHEOLOGY CONTROL AGENT BYK-Chemie GmbH (DE) 2025-10-29 EP claimed
US-20250302831-A1 THERAPY FOR ALCOHOL-RELATED LIVER DISEASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, OFFICE OF THE GENERAL COUNSEL (024) 2025-10-02 US claimed
CN-120078781-A Application of BET/AKT double-pathway active dihydroquinazolinone compound in preparation of anti-prostate cancer drugs 烟台大学 2025-06-03 CN claimed
CN-120058710-A Dihydroquinazolinone compounds and methods of making the same 烟台大学 2025-05-30 CN claimed
CN-119306689-A Method for synthesizing olefin and fluoroolefin 滁州学院 2025-01-14 CN claimed
EP-4204413-B1 DIHYDROQUINAZOLIN-2-ONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS USEFUL IN THE TREATMENT OF HIV MERCK SHARP & DOHME LLC (US) 2024-09-25 EP claimed
WO-1998027975-A1 POLY(ADP-RIBOSE) POLYMERASE INHIBITORS TO TREAT DISEASES ASSOCIATED WITH CELLULAR SENESCENCE GERON CORPORATION (US) 1998-07-02 WO claimed
US-5521315-A Olefin substituted long chain compounds CELL THERAPEUTICS, INC. (US) 1996-05-28 US claimed
EP-0677516-A1 Cyclic amide derivatives Eisai Co., Ltd. (JP) 1995-10-18 EP claimed
EP-0638309-A1 Substances inhibiting proteic adp ribosilation suitable to prevent the diabetes mellitus complications ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. (IT) 1995-02-15 EP claimed
EP-0468187-A2 Cyclic amide derivatives Eisai Co., Ltd. (JP) 1992-01-29 EP claimed
EP-0316630-A1 Novel fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition WARNER-LAMBERT COMPANY (US) 1989-05-24 EP claimed
EP-0076199-B1 TRIAZOLOQUINAZOLONES AND THEIR SALTS, PROCESS AND INTERMEDIATES FOR PREPARING THEM, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1986-12-30 EP claimed
US-4202974-A Process for preparing 3,4-dihydro-2(1H)-quinazolinone derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-05-13 US claimed
US-4099002-A QUINAZOLINONE DERIVATIVES AND A PROCESS FOR PRODUCTION THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1978-07-04 US claimed
US-4048168-A Process for preparing 1-polyhaloalkyl-3,4-dihydro-2-(1H)-quinazolinones SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-09-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492183-B2 Tetrahydroquinazoline derivatives as selective cytotoxic agents ACIN1, CD4, NFATC1 HTR5A 3791/4885AHR 3277/4885PDK2 2161/4885
US-20250302831-A1 THERAPY FOR ALCOHOL-RELATED LIVER DISEASE CHRNA4, CHRNB4, CHRNA1 HTR5A 1656/4885AHR 2652/4885PDK2 1813/4885
US-12558357-B2 Tetrahydroquinazoline derivatives as selective cytotoxic agents ACIN1, CD4, CCR8 HTR5A 3937/4885AHR 1988/4885PDK2 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.